Search clinical trials for: M-Vax- autologous, hapten-modified melanoma vaccine

Total 23 results

AVAX Technologies

Unknown

M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma

Melanoma
AVAX Technologies

Completed

Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

Melanoma

United States
AVAX Technologies

Unknown

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Adenocarcinoma of the Ovary

United States
AVAX Technologies

Terminated

DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer - Completely Resectable

United States
Muhimbili University of Health and Allied Sciences
Karolinska Institutet; Imperial College London; Medical Research Council; Ludwig-Maximilians... and other collaborators

Completed

A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique (TaMoVac II)

HIV | Safety | Immunogenicity | Vaccines

Tanzania, Mozambique
Maria Sklodowska-Curie National Research Institute...

Unknown

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Melanoma (Skin)

Poland
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); American Society of Clinical Oncology; Society...

Completed

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Hadassah Medical Organization

Unknown

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Metastatic Disease | High Risk HLA-A2+ Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Trial of Smallpox Vaccine

Healthy

United States
Mary Crowley Medical Research Center

Terminated

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer (Auto TAG)

Carcinoma, Advanced Metastatic

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Hadassah Medical Organization

Unknown

Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib (rcc)

Renal Cell Cancer
Dana-Farber Cancer Institute

Recruiting

GVAX Plus Checkpoint Blockade in Neuroblastoma

Neuroblastoma | Pediatric Solid Tumor

United States
GlaxoSmithKline
London School of Hygiene and Tropical Medicine; PATH; Medical Research Council... and other collaborators

Completed

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

Infections, Streptococcal

Gambia
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Gliosarcoma | Giant Cell Glioblastoma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Chiron Corporation

Completed

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

Kidney Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma

United States
ALK-Abelló A/S

Completed

Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)

Allergy | Rhinitis | Conjunctivitis | Rhinoconjunctivitis
Julio Ramirez
University of Louisville

Terminated

Patients Response to Early Switch To Oral:Osteomyelitis Study (PRESTO:Osteo)

Osteomyelitis

United States

Search clinical trials for: M-Vax- autologous, hapten-modified melanoma vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations